HC Wainwright & Co. Reiterates Buy on Olema Pharmaceuticals, Maintains $30 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Emily Bodnar has reiterated a Buy rating on Olema Pharmaceuticals (NASDAQ:OLMA) and maintained a $30 price target.
May 15, 2024 | 5:58 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
HC Wainwright & Co. has reiterated a Buy rating on Olema Pharmaceuticals and maintained a $30 price target, indicating continued confidence in the company's growth potential.
The reiteration of a Buy rating and maintenance of a $30 price target by a reputable analyst suggests strong confidence in Olema Pharmaceuticals' future performance, likely leading to positive investor sentiment and a potential short-term price increase.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100